ctDNA analysis across the cancer research continuum

19 October 2023

In this application note, Bio-Rad discusses the transformative impact of circulating tumor DNA (ctDNA) analysis on cancer research. Unlike invasive biopsies, ctDNA analysis offers a non-invasive, safer, and more efficient method for continuously monitoring tumor-derived genomic biomarkers, tumor evolution, treatment response, and recurrence. This approach, utilizing biofluid samples like blood, urine, plasma, and saliva, provides valuable prognostic information, enabling informed decisions about therapeutic strategies. The minimally invasive nature of ctDNA collection allows for easy repetition, facilitating longitudinal analyses. This longitudinal insight helps researchers monitor evolving tumor biology, detect emergent resistant mutations, and enhance the accuracy of predictive assays, ultimately advancing cancer research and treatment.